The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.
 
R. Donald Harvey
Consulting or Advisory Role - Amgen; Erasca, Inc; Janssen Oncology
Research Funding - Abbisko (Inst); Abbvie (Inst); ADC Therapeutics; GlaxoSmithKline (Inst); Incyte; Janssen Research & Development (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); MorphoSys; Nektar (Inst); Takeda (Inst); Xencor (Inst)
 
Joseph Franz
No Relationships to Disclose
 
Nisha S Joseph
Consulting or Advisory Role - GlaxoSmithKline; Janssen Biotech
Research Funding - Bristol Myers Squibb Foundation; Janssen Biotech; Novartis; Regeneron
 
Jonathan L. Kaufman
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Celgene; Genentech; Incyte; TG Therapeutics
Research Funding - Abbvie/Genentech (Inst); Amgen (Inst); BMS (Inst); Celgene (Inst); Fortis (Inst); Janssen (Inst); Merck (Inst); Sutro Biopharma (Inst)
 
Elise Hitron
No Relationships to Disclose
 
Hannah Collins
No Relationships to Disclose
 
Catherine Braga
No Relationships to Disclose
 
Kathryn T. Maples
Consulting or Advisory Role - GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi
 
Craig C. Hofmeister
Honoraria - Abbvie; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Oncopeptides
Research Funding - Bristol-Myers Squibb (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent related to REC-2282 (formerly AR-42, NSC D736012)
 
Madhav V. Dhodapkar
Consulting or Advisory Role - Janssen Oncology; lava therapeutics; Roche/Genentech
 
Sagar Lonial
Stock and Other Ownership Interests - TG Therapeutics
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb; Celgene; Takeda
Other Relationship - TG Therapeutics
 
Ajay K. Nooka
Honoraria - Adaptive Biotechnologies; Amgen; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb/Celgene; Cellectar; Genzyme; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Oncopeptides; ONK Therapeutics; Pfizer; Secura Bio; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Cellectar; Genzyme; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Oncopeptides; ONK Therapeutics; Pfizer; Secura Bio; Takeda
Research Funding - Amgen (Inst); Arch Oncology (Inst); Bristol-Myers Squibb/Celgene (Inst); Cellectar (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline